S. Govindan

发表

D. Goldenberg, S. Govindan, 2010 .

Two topologically distinct total syntheses of (±)-sarkomycin

T. Hudlický, F. Koszyk, S. Govindan, 1983 .

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

Edmund A. Rossi, Robert M. Sharkey, David M. Goldenberg, 2015, Oncotarget.

Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

D. Goldenberg, R. Sharkey, S. Govindan, 2011, Molecular Cancer Therapeutics.

Designing immunoconjugates for cancer therapy

D. Goldenberg, S. Govindan, 2012, Expert opinion on biological therapy.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

D. Goldenberg, R. Sharkey, S. Govindan, 2017, Molecular Cancer Therapeutics.

Prospects and progress of antibody-drug conjugates in solid tumor therapies

D. Goldenberg, R. Sharkey, S. Govindan, 2016, Expert opinion on biological therapy.

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

W. Mcbride, D. Goldenberg, R. Sharkey, 2015, Clinical Cancer Research.

Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

W. Mcbride, D. Goldenberg, R. Sharkey, 2015, Molecular pharmaceutics.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

M. Shah, P. Maliakal, D. Goldenberg, 2015, Clinical Cancer Research.

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

D. Goldenberg, R. Sharkey, D. Gold, 2013, Molecular Cancer Therapeutics.

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

D. Goldenberg, R. Sharkey, S. Govindan, 2011, Molecular Cancer Therapeutics.

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

D. Goldenberg, R. Sharkey, S. Govindan, 2011, Clinical Cancer Research.

New Antibody Conjugates in Cancer Therapy

D. Goldenberg, S. Govindan, 2010, TheScientificWorldJournal.

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

D. Goldenberg, H. Hansen, S. Govindan, 2008, Journal of medicinal chemistry.

Abstract 2904: SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science

Chien-Hsing Chang, Edmund A. Rossi, Robert M. Sharkey, 2014 .

Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel

G. Griffiths, D. Goldenberg, H. Hansen, 2004, Breast Cancer Research and Treatment.

CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms

D. Goldenberg, H. Hansen, S. Govindan, 2007, Clinical Cancer Research.

Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies

G. Griffiths, D. Goldenberg, H. Hansen, 2005, Technology in cancer research & treatment.

Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.

G. Griffiths, D. Goldenberg, R. Sharkey, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Anti-CD 74 Antibody-Doxorubicin Conjugate , IMMU-110 , in a HumanMultipleMyeloma Xenograft and inMonkeys

G. Griffiths, D. Goldenberg, I. Horak, 2005 .

CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

D. Goldenberg, H. Hansen, S. Govindan, 2009, Clinical Cancer Research.

Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

G. Griffiths, D. Goldenberg, H. Hansen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

290 Pharmacokinetics and tissue biodistribution of a doxorubicin-antibody conjugate in mice

G. Griffiths, D. Goldenberg, H. Hansen, 2004 .

The advantage of residualizing radiolabels for targeting B‐cell lymphomas with a radiolabeled anti‐CD22 monoclonal antibody

D. Goldenberg, R. Sharkey, S. Govindan, 1997, International journal of cancer.

Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates.

G. Griffiths, D. Goldenberg, S. Govindan, 2005, Nuclear medicine and biology.

Improved Iodine Radiolabels for Monoclonal Antibody Therapy 1

G. Griffiths, D. Goldenberg, H. Hansen, 2002 .

Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4–Labeled Antibody ch806

A. Scott, G. O'Keefe, Gareth Jones, 2010, Journal of Nuclear Medicine.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy of human colonic and lung cancer xenografts with SN-38 conjugates of anti-CEACAM5 and anti-EGP-1 humanized monoclonal antibodies

D. Goldenberg, H. Hansen, S. Govindan, 2007 .

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

P. Schwartz, D. Goldenberg, R. Sharkey, 2018, Gynecologic oncology reports.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

J. Hajdenberg, B. Faltas, S. Tagawa, 2016, Clinical genitourinary cancer.

Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody

G. Griffiths, D. Goldenberg, H. Hansen, 2005, Clinical Cancer Research.

Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.

G. Griffiths, D. Goldenberg, S. Govindan, 2002, Cancer biotherapy & radiopharmaceuticals.

TWO TOPOLOGICALLY DISTINCT TOTAL SYNTHESES OF (.+-.)-SARKOMYCIN

T. Hudlický, F. Koszyk, S. Govindan, 1984 .

Intramolecular cyclopentene annulation. III: Synthesis and carbon-13 nuclear magnetic resonance spectroscopy of bicyclic cyclopentene lactones as potential perhydroazulene and/or monoterpene synthons

T. Kulp, T. Hudlický, S. Govindan, 1983 .

Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

G. Griffiths, D. Goldenberg, H. Hansen, 2005, Clinical Cancer Research.

Synthesis and biological activity of analogs of fecapentaene-12.

D. Kingston, A. Gunatilaka, T. Wilkins, 1987, Journal of Natural Products.

Synthesis of 15-deoxy-16.beta.-ethoxybruceantin and synthetic efforts toward bruceantin

P. Fuchs, S. Govindan, C. Chiu, 1994 .

On the stereochemistry of fecapentaene-12.

D. Kingston, C. Duh, T. Wilkins, 1988, Journal of natural products.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

A. Bardia, W. Messersmith, P. Maliakal, 2017, Cancer.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

D. Goldenberg, R. Sharkey, S. Govindan, 2015, Bioconjugate chemistry.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J. Berlin, A. Bardia, R. Heist, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

D. Goldenberg, S. Govindan, Thomas M Cardillo, 2017, Molecular Cancer Therapeutics.

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

M. Shah, W. Messersmith, P. Maliakal, 2014 .

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

G. Griffiths, D. Goldenberg, R. Sharkey, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J. Berlin, R. Goldberg, J. Marshall, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results

A. Bardia, J. Diamond, J. O’Shaughnessy, 2018 .

Development of humanized antibodies as cancer therapeutics.

G. Griffiths, D. Goldenberg, H. Hansen, 2005, Methods.

Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies

G. Griffiths, D. Goldenberg, G. Sgouros, 1999, International journal of cancer.

Improved iodine radiolabels for monoclonal antibody therapy.

G. Griffiths, D. Goldenberg, H. Hansen, 2003, Cancer research.

Heteroatom cyclopentene annulation. Synthesis of guaiane ring system

T. Hudlický, S. Govindan, J. O. Frazier, 1985 .

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Greg M. Thurber, S. Govindan, S. Hofsess, 2022, Molecular cancer therapeutics.

INTRAMOLECULAR CYCLOPENTENE ANNULATION. 3. SYNTHESIS AND CARBON-13 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF BICYCLIC CYCLOPENTENE LACTONES AS POTENTIAL PERHYDROAZULENE AND/OR MONOTERPENE SYNTHONS

T. Kulp, T. Hudlický, S. Govindan, 1984 .

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

A. Bardia, M. Shah, W. Messersmith, 2015 .

Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.

G. Griffiths, D. Goldenberg, H. Hansen, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

D. Goldenberg, R. Sharkey, D. Gold, 2013, Molecular Cancer Therapeutics.

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

D. Goldenberg, R. Sharkey, S. Govindan, 2011, Clinical Cancer Research.

Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.

M. Brechbiel, G. Griffiths, D. Goldenberg, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

R. Sharkey, S. Govindan, Thomas M Cardillo, 2024, Oncotarget.

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

D. Goldenberg, R. Sharkey, S. Govindan, 2020, Oncotarget.